You are here

Director/PDMR Shareholding

Summit Therapeutics plc 
(‘Summit’ or the ’Company’)

Exercise of Restricted Stock Units, Director Dealings and Total Voting Rights

Oxford, UK, and Cambridge, MA, US, 24 October 2018 – Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM) announces the exercise by the following Non-Executive Directors of restricted stock units (‘RSUs’) that entitled the holder to subscribe for an ordinary share of one penny nominal value at a subscription price of one penny per ordinary share.  The RSUs were granted under the Company’s 2017 Remuneration Policy and were eligible for exercise for a limited time after completion of a vesting period of one year. Details of the exercise of the RSUs, all of which took place on 24 October 2018, and which have been duly notified to the Company, are summarised below.

DirectorPositionRSU’s Exercised
Frank ArmstrongNon-Executive Chairman41,666
Leopoldo ZambelettiNon-Executive Director19,444
Valerie AndrewsNon-Executive Director19,444
Dave WurzerNon-Executive Director19,444
Total 99,998

Summit has also been notified that Leopoldo Zambeletti has sold 11,358 ordinary shares, at a price of 28.1 pence per ordinary share to cover the tax and other charges associated with the exercise of the RSUs.

Following the exercise of the RSUs, the shareholdings of the Non-Executive Directors are as follows:

DirectorPositionShareholding
(ordinary shares)
% of Issued Share Capital
Frank ArmstrongNon-Executive Chairman122,204*0.15%
Leopoldo ZambelettiNon-Executive Director15,9790.02%
Valerie AndrewsNon-Executive Director49,1230.06%
Dave WurzerNon-Executive Director46,1230.06%
Total 233,4290.29%

* Includes shares held by persons closely associated with the director

The Company also announces the exercise of a further 38,888 RSUs by former Non-Executive Directors of Summit. 

Application has been made to the London Stock Exchange for the admission of 138,886 ordinary shares to trading on AIM and it is expected that admission will become effective and that dealings will commence at 8.00 a.m. on 30 October 2018.

Total Voting Rights
Following the exercise of these RSUs, the total number of ordinary shares following admission will be 82,264,881 with each ordinary share carrying the right to one vote. The Company has no shares in Treasury; therefore following admission the total number of voting rights in Summit will be 82,264,881. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify an interest in, or change to their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014 (MAR).

About Summit Therapeutics
Summit Therapeutics is a leader in antibiotic innovation. Our new mechanism antibiotics are designed to become the new standards of care for the benefit of patients, and create value for payors and healthcare providers. We are currently developing new mechanism antibiotics for C. difficile infection and gonorrhoea and are using our proprietary Discuva Platform to expand our pipeline. For more information, visit www.summitplc.com and follow us on Twitter @summitplc.

Contacts

Summit  
Glyn Edwards / Richard Pye (UK office)Tel:44 (0)1235 443 951
Erik Ostrowski / Michelle Avery (US office) +1 617 225 4455
   
Cairn Financial Advisers LLP (Nominated Adviser)Tel:+44 (0)20 7213 0880
Liam Murray / Tony Rawlinson  
   

Notification of Transactions pursuant to Article 19(1) of Regulation (EU) No. 596/2014

1Details of the persons discharging managerial responsibilities/person closely associated
a)Name
  1. Frank Armstrong
     
  2. Leopoldo Zambeletti
     
  3. Valerie Andrews
     
  4. Dave Wurzer
2Reason for the notification
a)Position / status
  1. Non-Executive Chairman
     
  2. Non-Executive Director
     
  3. Non-Executive Director
     
  4. Non-Executive Director
b)Initial notification / AmendmentInitial notification
3Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)NameSummit Therapeutics plc
b)LEI213800NRW8AOMYMTBD89
4Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)Description of the financial instrument, type of instrumentOrdinary shares of 1 penny each
  
Identification codeGB00BN40HZ01
b)Nature of the transactionsExercise of restricted stock units (RSUs) to subscribe for ordinary shares of one penny nominal value
c)Price(s) and volume(s) Price(s)Volume(s) 
(i)-(iv) 1p (exercise price)
 

 
  1. 41,666
 
(ii)-(iv) 19,444
 
d)Aggregated information

 

- Aggregated volume

 

- Price
 

 

99,998 ordinary shares

 

1 penny (exercise price)

 
e)Date of the transactions24 October 2018
f)Place of the transactionsOutside a trading venue


1Details of the persons discharging managerial responsibilities/person closely associated
a)Name
  1. Leopoldo Zambeletti
2Reason for the notification
a)Position / status
  1. Non-Executive Director
b)Initial notification / AmendmentInitial notification
3Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)NameSummit Therapeutics plc
b)LEI213800NRW8AOMYMTBD89
4Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)Description of the financial instrument, type of instrumentOrdinary shares of 1 penny each
  
Identification codeGB00BN40HZ01
b)Nature of the transactionsSale of ordinary shares of one penny nominal value
c)Price(s) and volume(s) Price(s)Volume(s) 
  1. 28.1 pence
  1. 11,358
 
d)Aggregated information

 

- Aggregated volume

 

- Average Price
 

 

11,358 ordinary shares

 

28.1 pence

 
e)Date of the transactions24 October 2018
f)Place of the transactionsLondon Stock Exchange

-END-

Wednesday, October 24, 2018 - 11:15